» Articles » PMID: 38341085

Altered States and Social Bonds: Effects of MDMA and Serotonergic Psychedelics on Social Behavior As a Mechanism Underlying Substance-Assisted Therapy

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

There has been renewed interest in the use of 3,4-methylenedioxy-methamphetamine (MDMA) and serotonergic psychedelics in the treatment of multiple psychiatric disorders. Many of these compounds are known to produce prosocial effects, but how these effects relate to therapeutic efficacy and the extent to which prosocial effects are unique to a particular drug class is unknown. In this article, we present a narrative overview and compare evidence for the prosocial effects of MDMA and serotonergic psychedelics to elucidate shared mechanisms that may underlie the therapeutic process. We discuss 4 categories of prosocial effects: altered self-image, responses to social reward, responses to negative social input, and social neuroplasticity. While both categories of drugs alter self-perception, MDMA may do so in a way that is less related to the experience of mystical-type states than serotonergic psychedelics. In the case of social reward, evidence supports the ability of MDMA to enhance responses and suggests that serotonergic psychedelics may also do so, but more research is needed in this area. Both drug classes consistently dampen reactivity to negative social stimuli. Finally, preclinical evidence supports the ability of both drug classes to induce social neuroplasticity, promoting adaptive rewiring of neural circuits, which may be helpful in trauma processing. While both MDMA and serotonergic psychedelics produce prosocial effects, they differ in the mechanisms through which they do this. These differences affect the types of psychosocial interventions that may work best with each compound.

References
1.
Duerler P, Schilbach L, Stampfli P, Vollenweider F, Preller K . LSD-induced increases in social adaptation to opinions similar to one's own are associated with stimulation of serotonin receptors. Sci Rep. 2020; 10(1):12181. PMC: 7376162. DOI: 10.1038/s41598-020-68899-y. View

2.
Wagner M, Mithoefer M, Mithoefer A, MacAulay R, Jerome L, Yazar-Klosinski B . Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy. J Psychopharmacol. 2017; 31(8):967-974. PMC: 5544120. DOI: 10.1177/0269881117711712. View

3.
Fluckiger C, Del Re A, Wampold B, Horvath A . The alliance in adult psychotherapy: A meta-analytic synthesis. Psychotherapy (Chic). 2018; 55(4):316-340. DOI: 10.1037/pst0000172. View

4.
Calder A, Hasler G . Extrapharmacological Safety Topics in Psychedelic-Assisted Psychotherapy. JAMA Psychiatry. 2023; 80(8):761-762. DOI: 10.1001/jamapsychiatry.2023.1031. View

5.
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R . Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021; 384(15):1402-1411. DOI: 10.1056/NEJMoa2032994. View